Healthcare provider profile · identity verified

Heather L. Tiska, MD

Internal Medicine · SACRAMENTO, CA · NPI 1629156104

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	446	152
Levothyroxine Sodium	Levothyroxine Sodium	355	107
Amlodipine Besylate	Amlodipine Besylate	336	106
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	313	60
Losartan Potassium	Losartan Potassium	237	80
Trazodone Hcl	Trazodone Hcl	221	47
Lisinopril	Lisinopril	220	73
Hydrochlorothiazide	Hydrochlorothiazide	176	64
Pantoprazole Sodium	Pantoprazole Sodium	165	44
Fluticasone Propionate	Fluticasone Propionate	164	56
Furosemide	Furosemide	153	56
Alendronate Sodium	Alendronate Sodium	144	45
Gabapentin	Gabapentin	142	48
Duloxetine Hcl	Duloxetine Hcl	135	45
Famotidine	Famotidine	132	50
Albuterol Sulfate Hfa	Albuterol Sulfate	123	68
Metoprolol Succinate	Metoprolol Succinate	114	42
Ibuprofen	Ibuprofen	113	40
Omeprazole	Omeprazole	99	34
Lorazepam	Lorazepam	95	22
Metformin Hcl Er	Metformin Hcl	90	27
Simvastatin	Simvastatin	86	30
Alprazolam	Alprazolam	79	suppressed
Tizanidine Hcl	Tizanidine Hcl	76	22
Atenolol	Atenolol	74	27
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	68	suppressed
Sertraline Hcl	Sertraline Hcl	67	23
Tamsulosin Hcl	Tamsulosin Hcl	66	28
Prednisone	Prednisone	64	43
Oxycodone Hcl	Oxycodone Hcl	62	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	61	18
Alvesco	Ciclesonide	60	27
Fluoxetine Hcl	Fluoxetine Hcl	60	22
Metoprolol Tartrate	Metoprolol Tartrate	60	19
Potassium Chloride	Potassium Chloride	58	24
Acyclovir	Acyclovir	57	22
Cephalexin	Cephalexin	57	42
Montelukast Sodium	Montelukast Sodium	55	18
Triamcinolone Acetonide	Triamcinolone Acetonide	54	23
Lovastatin	Lovastatin	53	16
Clobetasol Propionate	Clobetasol Propionate	50	24
Estradiol	Estradiol	50	15
Rosuvastatin Calcium	Rosuvastatin Calcium	50	17
Temazepam	Temazepam	50	suppressed
Tramadol Hcl	Tramadol Hcl	49	suppressed
Donepezil Hcl	Donepezil Hcl	46	12
Citalopram Hbr	Citalopram Hydrobromide	45	13
Jardiance	Empagliflozin	45	15
Sumatriptan Succinate	Sumatriptan Succinate	45	suppressed
Meloxicam	Meloxicam	44	15
Ropinirole Hcl	Ropinirole Hcl	44	suppressed
Ondansetron Odt	Ondansetron	42	20
Wixela Inhub	Fluticasone Propion/Salmeterol	42	suppressed
Baclofen	Baclofen	41	17
Glipizide	Glipizide	41	15
Metformin Hcl	Metformin Hcl	41	13
Doxycycline Monohydrate	Doxycycline Monohydrate	40	29
Propranolol Hcl	Propranolol Hcl	39	14
Terazosin Hcl	Terazosin Hcl	38	12
Clopidogrel	Clopidogrel Bisulfate	37	12
Glipizide Er	Glipizide	37	13
Bupropion Xl	Bupropion Hcl	35	suppressed
Spiriva Respimat	Tiotropium Bromide	34	11
Allopurinol	Allopurinol	33	11
Hydrocortisone	Hydrocortisone	33	18
Ozempic	Semaglutide	32	suppressed
Azithromycin	Azithromycin	31	21
Ondansetron Hcl	Ondansetron Hcl	31	11
Trospium Chloride	Trospium Chloride	31	suppressed
Breyna	Budesonide/Formoterol Fumarate	30	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	29	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	28	13
Nortriptyline Hcl	Nortriptyline Hcl	27	suppressed
Clonazepam	Clonazepam	26	suppressed
Eliquis	Apixaban	24	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	24	suppressed
Nabumetone	Nabumetone	24	suppressed
Mirtazapine	Mirtazapine	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Pregabalin	Pregabalin	22	suppressed
Synthroid	Levothyroxine Sodium	22	suppressed
Spironolactone	Spironolactone	21	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	21	suppressed
Cefadroxil	Cefadroxil	20	19
Morphine Sulfate Er	Morphine Sulfate	20	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Nystatin	Nystatin	18	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	15
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Mupirocin	Mupirocin	17	suppressed
Rizatriptan	Rizatriptan Benzoate	17	suppressed
Valacyclovir	Valacyclovir Hcl	17	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	16	16
Azelastine Hcl	Azelastine Hcl	16	suppressed
Climara	Estradiol	16	suppressed
Carvedilol	Carvedilol	15	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	15	suppressed
Metronidazole	Metronidazole	15	suppressed
Finasteride	Finasteride	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Promethazine Hcl	Promethazine Hcl	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Epinephrine	Epinephrine	13	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	13	suppressed
Risperidone	Risperidone	13	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Fentanyl	Fentanyl	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Topiramate	Topiramate	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Buprenorphine	Buprenorphine	11	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Ibandronate Sodium	Ibandronate Sodium	11	suppressed
Naproxen	Naproxen	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11
Pravastatin Sodium	Pravastatin Sodium	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error